OBJECTIVES:  Oral contraceptives are effective in the prevention of unplanned pregnancy, but are associated with low adherence and may result in contraceptive failure. Long acting reversible contraceptive methods combine reversibility with high effectiveness. This analysis aimed to estimate the projection of costs using the etonogestrel implant and the levonorgestrel intrauterine system for five years, from the private health perspective of Brazil. METHODS:  The eligible population was female beneficiaries in September 2016, aged 19 to 48 years. Cost and market-share of contraceptives data were obtained from local sources. The prices for etonogestrel implant and levonorgestrel intrauterine system were 902.85 BRL and 760.33 BRL, in addition to 173.5 BRL and 236.52 BRL, respectively, as reimbursement by procedure. For levonorgestrel intrauterine system, it was also considered a hysteroscopy or surgical curettage in 25% of cases in the base case and 75% in the alternative scenario. RESULTS:  In five years, the budget impact in the base case was 1,583,792,751 BRL and 1,560,566,016 BRL without and with the inclusion of etonogestrel implant, respectively, resulting in savings of 23,226,735 BRL. In the alternative scenario, savings with the inclusion of etonogestrel implant would be of 106,230,590 BRL. CONCLUSIONS: The inclusion of the etonogestrel implant in private health sector in Brazil could save from 23.2 to 106.2 million reals, depending on the rate of hysteroscopy, supplementing the contraceptive options for Brazilian women, also having fewer clinical restrictions compared to use of the levonorgestrel intrauterine system.